Skip to main content

Table 2 Demographic, breed and surgery variables; data are mean (± SD) or number of dogs (%)

From: Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs

Variable Robenacoxib Placebo Total P value*
Number of dogs 119 (49.8%) 120 (50.2%) 239 (100.0%)  
Age (years) 6.2 (±4.3) 5.5 (±3.8) 5.8 (±4.0) 0.23
Body weight (kg), pre-enrollment 20.0 (±12.2) 22.9 (±15.1) 21.5 (±13.8) 0.10
Sex and neutered status     0.068
 Female intact 40 (33.6%) 33 (27.5%) 73 (30.5%)
 Female spayed 36 (30.3%) 34 (28.3%) 70 (29.3%)
 Male intact 7 (5.9%) 20 (16.7%) 27 (11.3%)
 Male castrated 36 (30.3%) 33 (27.5%) 69 (28.9%)
Breed     0.65
 Labrador Retriever 11 (9.2%) 14 (11.7%) 25 (10.5%)
 Golden Retriever 10 (8.4%) 5 (4.2%) 15 (6.3%)
 Mix-Labrador Retriever 5 (4.2%) 7 (5.8%) 12 (5.0%)
 Shih Tzu 6 (5.0%) 5 (4.2%) 11 (4.6%)
 Various other breeds 87 (73.1%) 89 (74.2%) 176 (73.6%)
Type of surgery     0.62
 Skin tumor removal (≥ 8 cm in size) 31 (26.1%) 39 (32.5%) 70 (29.3%)
 Ovariohysterectomy 29 (24.4%) 26 (21.7%) 55 (23.0%)
 Cystotomy 18 (15.1%) 17 (14.2%) 35 (14.6%)
 Gastropexy 12 (10.1%) 16 (13.3%) 28 (11.7%)
 Other soft tissue surgery 29 (24.4%) 22 (18.3%) 51 (21.3%)
  1. *Significance of differences between treatment groups (based on t-test for continuous variables and χ2 test for categorical variables)